ambroxol has been researched along with Drug Hypersensitivity in 1 studies
Ambroxol: A metabolite of BROMHEXINE that stimulates mucociliary action and clears the air passages in the respiratory tract. It is usually administered as the hydrochloride.
Drug Hypersensitivity: Immunologically mediated adverse reactions to medicinal substances used legally or illegally.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this pilot was to assess the tolerability and efficacy of ambroxol as a pharmacological chaperone in patients with symptomatic, type 1 Gaucher disease who present with measurable disease parameters but are not receiving enzyme replacement therapy (ERT) in order to provide proof of concept and/or ascertain the suitability of ambroxol for a larger clinical trial." | 9.17 | Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. ( Altarescu, G; Elstein, D; Zimran, A, 2013) |
| "The purpose of this pilot was to assess the tolerability and efficacy of ambroxol as a pharmacological chaperone in patients with symptomatic, type 1 Gaucher disease who present with measurable disease parameters but are not receiving enzyme replacement therapy (ERT) in order to provide proof of concept and/or ascertain the suitability of ambroxol for a larger clinical trial." | 5.17 | Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease. ( Altarescu, G; Elstein, D; Zimran, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zimran, A | 1 |
| Altarescu, G | 1 |
| Elstein, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ambroxol as a Novel Disease Modifying Treatment for Parkinson's Disease Dementia[NCT02914366] | Phase 2 | 55 participants (Actual) | Interventional | 2015-11-30 | Active, not recruiting | ||
| Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia[NCT04405596] | Phase 1/Phase 2 | 15 participants (Anticipated) | Interventional | 2025-01-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for ambroxol and Drug Hypersensitivity
| Article | Year |
|---|---|
Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.
Topics: Adult; Ambroxol; Drug Hypersensitivity; Enzyme Stability; Female; Gaucher Disease; Glucosylceramidas | 2013 |
Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.
Topics: Adult; Ambroxol; Drug Hypersensitivity; Enzyme Stability; Female; Gaucher Disease; Glucosylceramidas | 2013 |
Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.
Topics: Adult; Ambroxol; Drug Hypersensitivity; Enzyme Stability; Female; Gaucher Disease; Glucosylceramidas | 2013 |
Pilot study using ambroxol as a pharmacological chaperone in type 1 Gaucher disease.
Topics: Adult; Ambroxol; Drug Hypersensitivity; Enzyme Stability; Female; Gaucher Disease; Glucosylceramidas | 2013 |